Court Tweaks ANDA Suit Standards, May Widen Declaratory Judgment Window
This article was originally published in The Tan Sheet
Executive Summary
The parameters under which generic drug firms can seek declaratory judgments against patent holders could be expanded in a March 30 ruling by the U.S. Court of Appeals for the Federal Circuit